Tango (TNGX) Q2 Revenue Drops 52%
Tango Therapeutics (NASDAQ:TNGX), a biotechnology firm advancing targeted oncology therapies, posted its second quarter results on August 5, 2025. The highlight of the release was a steep decline in GAAP revenue, well below consensus, along with a larger net loss compared to analyst expectations. Revenue (GAAP) came in at $3.2 million—less than half of the $6.7 million estimate and a 59% drop compared to the same period in 2024. GAAP loss per share widened to ($0.35), compared to an expected ($0.34). The quarter was marked by meaningful clinical progress and disciplined R&D spending, but overshadowed by revenue pressures and the decision to end the Gilead partnership research term a year early. Overall, the period demonstrated pipeline advancement but heightened financial risk from falling collaborative income and increasing net losses.
Source: Analyst estimates for the quarter provided by FactSet.
Tango Therapeutics is a biotechnology firm specializing in the development of targeted cancer therapies through synthetic lethality—a method that selectively eliminates cancer cells based on their genetic profile. This approach allows for therapies that specifically attack tumors with particular genomic alterations, aiming to reduce harm to healthy tissue.
Source Fool.com
